Roivant Sciences (87S) Price & Analysis

2 Followers

87S Stock Chart & Stats

€28.93

-€0.81(-2.70%)

At close: Jul 29 4:00 PM EDT

€28.93

-€0.81(-2.70%)

Day’s Range― - ―

52-Week Range€14.63 - €35.82

Previous CloseN/A

Volume0.00

Average Volume (3M)24.00

Market Cap

€22.33B

Enterprise Value€22.46B

Total Cash (Recent Filing)€3.84B

Total Debt (Recent Filing)€107.15M

Price to Earnings (P/E)―

Beta0.28

Next Earnings

Nov 16, 2026

EPS Estimate

-0.33

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.38

Shares Outstanding722,323,000

10 Day Avg. Volume0

30 Day Avg. Volume24

Financial Highlights & Ratios

PEG Ratio-0.81

Price to Book (P/B)4.25

Price to Sales (P/S)2326.88

P/FCF Ratio-25.34

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€41.99

Price Target Upside45.13% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering12

EPS Forecast (FY)-1.23

Revenue Forecast (FY)€46.44M

Bulls Say, Bears Say

Bulls Say

First-in-class Product ApprovalFDA approval gives Roivant an established commercial product in an underserved rare disease, while first-in-class positioning and demonstrated symptom and steroid-sparing benefits may support durable adoption. Immediate availability also enables the company to begin converting clinical differentiation into recurring revenue.

Promising PH-ILD PipelineThe positive Phase 2 signal and rapid progression into a global Phase 3 study strengthen Roivant’s medium-term pipeline. Mosliciguat could address substantial unmet need in PH-ILD, adding a potentially differentiated growth avenue beyond the newly approved dermatomyositis therapy.

Strong Balance-sheet FlexibilityVery low leverage gives Roivant meaningful financial flexibility to fund clinical development, launches, and operating needs without relying heavily on new debt. This capital base can help sustain investment across several programs and provide resilience while pipeline assets mature.

Bears Say

Substantial Ongoing Cash BurnLarge recurring operating and free-cash-flow deficits show that Roivant’s development model currently consumes substantial cash before its pipeline can generate broad commercial returns. Continued burn may reduce financial flexibility over time and keeps execution dependent on its existing capital resources.

Persistent Unprofitability And Weak Revenue TrendDeclining revenue combined with significant net and operating losses indicates that commercial income is not yet covering the cost of the portfolio. Volatile results and negative returns on equity reduce earnings predictability, making sustained profitability dependent on successful launches and pipeline conversion.

Clinical And Commercial Execution UncertaintyRoivant’s medium-term progress remains exposed to trial design, regulatory, and market-adoption risks across several programs. Uncertain translation of clinical effects, class-level JAK safety concerns, and limited launch metrics could delay approvals, constrain uptake, or make outcomes less predictable.

Roivant Sciences News

Roivant, Priovant report CLARITY-1 and CLARITY-2 trials meet primary endpoint

Roivant and Priovant Therapeutics announced results from the Phase 3 CLARITY program evaluating brepocitinib in non-infectious uveitis, or...

3h ago

ROIV

Chardan biotech/pharma analysts hold analyst/industry conference call

Biotech & Pharma Analysts discuss pulmonary arterial hypertension (PAH) and PAH associated with interstitial lung disease (PH-ILD) (relevant...

8d ago

IKT

GOSS

Citi opens ‘upside 90-day catalyst watch’ on Roivant Sciences

Citi analyst Samantha Semenkow added an “upside 90-day catalyst watch” on Roivant Sciences (ROIV) while keeping a Buy...

9d ago

ROIV

Roivant Sciences downgraded to Peer Perform from Outperform at Wolfe Research

Wolfe Research downgraded Roivant Sciences (ROIV) to Peer Perform from Outperform with no price target The stock profile...

9d ago

ROIV

Wainwright maintains confidence in Immunovant’s pipeline despite CLE setback

H.C. Wainwright analyst Douglas Tsao notes that this morning, Roivant Sciences (ROIV) reported that IMVT-1402 missed the Week...

28d ago

IMVT

ROIV

Roivant Sciences price target raised to $41 from $37.50 at BofA

BofA analyst Chi Fong raised the firm’s price target on Roivant Sciences (ROIV) to $41 from $37.50 and...

28d ago

IMVT

ROIV

Roivant announces trial of IMVT-1402 did not reach statistical significance

Roivant announced topline results from Period 1 of Immunovant’s proof-of-concept trial evaluating IMVT-1402 for the treatment of cutaneous...

28d ago

ROIV

Roivant reports strong Phase 3 data in uveitis

Roivant Sciences ( ($ROIV) ) has issued an update. On October 21, 2026, Roivant and its subsidiary Priovant...

3h ago

ROIV

Roivant Shareholders Approve Directors and Governance Matters

An update from Roivant Sciences ( ($ROIV) ) is now available. On September 16, 2026, Roivant Sciences Ltd....

1M ago

ROIV

Roivant Sciences initiated with a Buy at Stifel

Stifel initiated coverage of Roivant Sciences (ROIV) with a Buy rating and $51 price target The company offers...

1M ago

ROIV

Roivant Sciences price target raised to $55 from $50 at TD Cowen

TD Cowen raised the firm’s price target on Roivant Sciences (ROIV) to $55 from $50 and keeps a...

1M ago

ROIV

Roivant Sciences price target raised to $46 from $42 at Guggenheim

Guggenheim raised the firm’s price target on Roivant Sciences (ROIV) to $46 from $42 and keeps a Buy...

1M ago

ROIV

Roivant advances mosliciguat with positive Phase 2 results

An announcement from Roivant Sciences ( ($ROIV) ) is now available. On September 8, 2026, Roivant reported positive...

1M ago

ROIV

Lisraya Pricing Upside and Measured Launch Drive Modest Roivant Target Increase to $37.50, Supporting Hold Rating Amid Balanced Risk/Reward

Roivant Sciences, the Healthcare sector company, was revisited by a Wall Street analyst on August 28. Analyst Chi...

2M ago

ROIV

87S FAQ

What was Roivant Sciences’s price range in the past 12 months?

Roivant Sciences lowest stock price was €14.63 and its highest was €35.82 in the past 12 months.

What is Roivant Sciences’s market cap?

Roivant Sciences’s market cap is €22.33B.

When is Roivant Sciences’s upcoming earnings report date?

Roivant Sciences’s upcoming earnings report date is Nov 16, 2026 which is in 26 days.

How were Roivant Sciences’s earnings last quarter?

Roivant Sciences released its earnings results on Aug 06, 2026. The company reported -€0.298 earnings per share for the quarter, missing the consensus estimate of -€0.267 by -€0.031.

Is Roivant Sciences overvalued?

According to Wall Street analysts Roivant Sciences’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Roivant Sciences pay dividends?

Roivant Sciences does not currently pay dividends.

What is Roivant Sciences’s EPS estimate?

Roivant Sciences’s EPS estimate is -0.33.

How many shares outstanding does Roivant Sciences have?

Roivant Sciences has 722,323,000 shares outstanding.

What happened to Roivant Sciences’s price movement after its last earnings report?

Roivant Sciences reported an EPS of -€0.298 in its last earnings report, missing expectations of -€0.267. Following the earnings report the stock price went down -0.101%.

Which hedge fund is a major shareholder of Roivant Sciences?

Currently, no hedge funds are holding shares in DE:87S

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Roivant Sciences Stock Smart Score

Outperform

Fundamentals

Return on Equity

-6.12%

Trailing 12-Months

Asset Growth

5.44%

Trailing 12-Months

Learn more about TipRanks Smart Score

Top Smart Score Stocks >

Company Description

Roivant Sciences

Roivant Sciences Ltd. is a biopharmaceutical and healthcare technology company dedicated to discovering and advancing innovative therapeutic drugs. The firm's development pipeline targets a broad spectrum of diseases, including various forms of solid tumors and oncologic malignancies, hematological disorders like sickle cell disease and warm autoimmune hemolytic anemia, as well as rare conditions such as hypophosphatasia. Additionally, Roivant is developing treatments for immunological and dermatological ailments, including psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, thyroid eye diseases, and sarcoidosis, alongside tackling infections like staph aureus bacteremia. Founded in 2014, its operations are based in London, United Kingdom.

Roivant Sciences (87S) Earnings & Revenues

Historic Earnings Reports

87S Company Deck

87S Earnings Call

Q1 2026

0:00 / 0:00

Earnings Call Sentiment|Positive

The call emphasized strong pipeline progress (potential DM launch, Phase III initiation in cutaneous sarcoidosis, multiple H2 2026 readouts), a sizable settlement cash inflow, active share buybacks, and continued R&D investment. Management was candid about clinical and regulatory risks (placebo variability, translation risk for PH‑ILD, randomized withdrawal uncertainty in D2T RA), limited early commercial visibility, JAK class safety perceptions, and contingent litigation outcomes. On balance, the positives (multiple near-term catalysts, strengthened balance sheet, active capital return, and robust R&D investment) outweigh the enumerated risks, which are largely development and execution uncertainties the company is actively managing.View all DE:87S earnings summaries

87S Stock 12 Month Forecast

Average Price Target

€41.99

▲(45.13% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"11":"€11","50":"€50","20.75":"€20.8","30.5":"€30.5","40.25":"€40.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":49.02808515,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€49.03</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":41.985869283,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€41.99</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":35.6567892,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€35.66</span>\n  </div></div>","useHTML":true}}],"tickPositions":[11,20.75,30.5,40.25,50],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,31.77,33.097545011538465,34.425090023076926,35.75263503461539,37.08018004615385,38.40772505769231,39.73527006923077,41.062815080769234,42.390360092307695,43.71790510384616,45.04545011538462,46.37299512692308,47.70054013846154,{"y":49.02808515,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,31.77,32.55583609869231,33.34167219738462,34.127508296076925,34.91334439476923,35.69918049346154,36.48501659215385,37.270852690846155,38.05668878953846,38.84252488823077,39.62836098692308,40.414197085615385,41.20003318430769,{"y":41.985869283,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,31.77,32.068983784615384,32.36796756923077,32.66695135384615,32.96593513846154,33.26491892307692,33.56390270769231,33.862886492307695,34.161870276923075,34.46085406153846,34.75983784615384,35.05882163076923,35.35780541538461,{"y":35.6567892,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":12.455,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.9,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.52,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.165,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.09,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.04,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.67,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.54,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.21,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.02,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.79,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.03,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.77,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >